KRAS and cancer: Oncogenic PI3K or K-Ras activation of mTORC1 is mediated, in part, through SREBPs, inducing de novo lipogenesis to promote tumor growth and proliferation with increased SREBP-2 expression correlating with poor prognosis in cancer patients (Figure 4) [62,78].